Pune, India, June 13, 2022 (GLOBE NEWSWIRE) —
As per a recent industry report put forward by Graphical Research, the Asia Pacific choline chloride market is forecast to register its name in the million-dollar fraternity down the line of seven years, by exceeding a revenue of USD 235 million by 2026.
With a rising need for effective treatments for a range of physiological and mental disorders, Asia Pacific choline chloride market trends are directed toward increased consumption by pharmaceutical companies. As indicated by the FDA approved Protara’s intravenous choline chloride, the demand for effective intestinal failure-associated liver disease (IFALD) treatments for patients dependent on parenteral nutrition has been augmenting.
Access sample pages of the report, “Asia Pacific Choline Chloride Market Forecasts 2026” in detail along with the table of contents (ToC) @
https://www.graphicalresearch.com/request/1582/sample
Faulty lifestyle factors such as excessive smoking and drinking are adding to the number of patients suffering from liver conditions in the region. Due to the constant advancements in the medical, nutraceuticals, and animal feed industries, new technologies are facilitating more usage of the product across the countries in Asia Pacific.
Trace the following 4 developments to stay updated of Asia Pacific choline chloride market trends:
- Role in livestock productivity
Choline chloride-based animal feed products come with a…
